Bias and Pancreatic Cancer Reporting
Menée à partir de données portant sur 1 835 patients atteints d'un adécocarcinome du pancréas de stade localisé, cette étude internationale rétrospective évalue l'efficacité, du point de vue de la survie globale, d'une chimiothérapie de première ligne de type FOLFORINOX
In this issue of the Journal, Jansen et al publish the first results of the “Trans-Atlantic Pancreatic Surgery” (TAPS) consortium (1). In considering the assembly of data from selected institutions, there a number of important issues related to potential for bias that must be taken into account when interpreting the findings. First, the nature of the consortium itself, five self-selected high-volume centers with multi-disciplinary teams for treatment of pancreatic cancer raises question of bias.
Journal of the National Cancer Institute , éditorial, 2021